MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in investor conferences in March 2024, including TD Cowen’s 44th Annual Health Care Conference, Leerink Partners 2024 Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference. The President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will be actively involved in various discussions and meetings during these events.

ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2024:

• TD Cowen’s 44^th Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a Prostate Cancer Corporate Panel Discussion on Monday, March 4, 2024, at 10:30 am ET.  MacroGenics’ management will also participate in one-on-one meetings.
• Leerink Partners 2024 Global Biopharma Conference (Miami). Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, March 12, 2024, at 9:20 am ET.  MacroGenics’ management will also participate in one-on-one meetings.
• Barclays 26^th Annual Global Healthcare Conference (Miami). Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, March 13, 2024, at 10:15 am ET.  MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

When will MacroGenics participate in TD Cowen’s 44th Annual Health Care Conference?

MacroGenics will participate in TD Cowen’s 44th Annual Health Care Conference on Monday, March 4, 2024, at 10:30 am ET.

Who will be involved in the Prostate Cancer Corporate Panel Discussion during the conference?

MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the Prostate Cancer Corporate Panel Discussion.

When will Scott Koenig participate in a fireside chat at Leerink Partners 2024 Global Biopharma Conference?

Scott Koenig will participate in a fireside chat at Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024, at 9:20 am ET.

Which conference will MacroGenics attend on Wednesday, March 13, 2024?

MacroGenics will attend Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024.

Where can webcasts of the presentations be accessed?

Webcasts of the presentations may be accessed under 'Events & Presentations' in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

How long will archived replays of the webcasts be available on the website?

The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.